-
Views
-
Cite
Cite
Nicolas Richard, Nadia Arab-Hocine, Margot Vannier, Rachida Leblanc-Boubchir, Agnès Pelaquier, Arnaud Boruchowicz, Marietta Musikas, Morgane Amil, Mathurin Fumery, Stéphane Nahon, Ramuntcho Arotcarena, Eve Gelsi, Arnaud Maurin, Xavier Hébuterne, Guillaume Savoye, Efficacy of ferric carboxymaltose on haemoglobin response among older patients with gastrointestinal bleeding: a randomised clinical trial, Age and Ageing, Volume 53, Issue 5, May 2024, afae085, https://doi.org/10.1093/ageing/afae085
Close - Share Icon Share
Abstract
Acute gastrointestinal bleeding (AGIB) is common in older patients but the use of iron in this context remains understudied.
This study aimed to evaluate prospectively the efficacy of ferric carboxymaltose to treat anaemia in older patients after AGIB.
This randomised double-blinded placebo-controlled clinical trial was conducted in 10 French centres. Eligible patients were 65 years or more, had controlled upper or lower gastrointestinal bleeding and a haemoglobin level of 9–11 g/dl. Patients were randomly assigned, in a 1:1 ratio, to receive either one intravenous iron injection of ferric carboxymaltose or one injection of saline solution. The primary endpoint was the difference in haemoglobin level between day 0 and day 42. Secondary endpoints were treatment-emergent adverse events, serious adverse events, rehospitalisation and improvement of quality of life (QOL) at day 180.
From January 2013 to January 2017, 59 patients were included. The median age of patients was 81.9 [75.8, 87.3] years. At day 42, a significant difference in haemoglobin level increase was observed (2.49 g/dl in the ferric carboxymaltose group vs. 1.56 g/dl in the placebo group, P = 0.02). At day 180, QOL, measured on European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, improved by 10.5 points in the ferric carboxymaltose group and by 8.2 points in the placebo group (P = 0.56). Rates of adverse events and rehospitalisation were similar in the two groups.
Intravenous iron seems safe and effective to treat anaemia in older patients after AGIB and should be considered as a standard-of-care treatment. ClinicalTrials.gov (NCT01690585).
Comments